To report the distribution of histopathological diagnoses in patients who underwent excision of localised limbal lesions that were clinically suspected to be squamous neoplasia (intra-epithelial neoplasia or squamous cell carcinoma). Methods 162 consecutive patients of a single ocular oncologist underwent an excisional biopsy between 1998 and 2009 for suspected squamous neoplasia. Histopathological reports were retrospectively reviewed. Results The population comprised 122 males and 40 females. The mean age was 63.4615.8 (range: 27e90). 138 (85.2%) lesions were identified as intraepithelial neoplasia (CIN), of which 34 (21.0%) were CIN I, 32 (19.8%) were CIN II and 72 (44.4%) were CIN III or squamous cell carcinoma in situ. In seven (4.3%) cases, the lesion was invasive squamous cell carcinoma. In two (1.2%) cases, the lesion was amelanotic malignant melanoma. In 16 (9.9%) cases, histopathology revealed a benign entity including lesions described as squamous papilloma, solar elastosis and epithelial hyperplasia, keratosis or reactive atypia. Conclusions In this population, for an experienced ocular oncologist, the misdiagnosis of localised limbal squamous neoplasia occurred in 10.5% of cases, with 5.5% of cases being malignant. This study highlights the importance of acquiring a clinical diagnosis before administering a topical chemotherapeutic agent.
INTRODUCTION
The term ocular surface squamous neoplasia (OSSN) is used to describe a wide variety of precancerous and cancerous tumours of the squamous epithelium, from increasing grades of dysplasia (conjunctival intraepithelial neoplasia (CIN)) to invasive squamous cell carcinoma (SCC). Clinically, they most frequently appear as focal epibulbar lesions at the corneoscleral limbus within the interpalpebral fissure.
The general morphological appearance of OSSN is described as gelatinous, with surrounding superficial vessels; papilliform, having a papillary appearance or leukoplakic, with an overlying white keratin plaque. 1e3 It is generally acknowledged that the grade of dysplasia cannot be consistently determined on clinical inspection alone. 2 The main differential diagnoses for localised limbal OSSN include pinguecula, pterygium and squamous papilloma. 3 4 In this paper, we describe the distribution of histopathological diagnoses in patients who underwent limbal excision for presumed OSSN less than four clock hours in extent. The study population is Australian, a population previously known to have a high incidence of OSSN. 5 
METHODS
The histopathological reports of patients who underwent excisional biopsy between January 1998 and March 2009 for a localised limbal lesion clinically suspected to be OSSN were examined. Recurrent lesions and non-limbal lesions were excluded from the study.
The study population is drawn from the practice of a single ocular oncologist (JM) in Adelaide, Australia. It is standard practice that all localised limbal lesions clinically suspected of being OSSN are excised superficially from the cornea and limbus with a 2-mm margin on the conjunctival aspect. In each case, excision was performed in an operating theatre. Over the study period, one patient with clinically suspected localised OSSN refused surgical excision and underwent primary topical chemotherapy.
Biopsy specimens were processed flat and embedded, on edge in a paraffin mould. Biopsies were orientated obliquely to the microtome blade to facilitate cutting of the sections. For all lesions suspected to be OSSN, three levels were examined routinely; additional levels were examined if required. No routine special stains were performed. A single, experienced, ocular pathologist (TD) reviewed and reported all specimens. OSSN was graded according to the following definitions: < CIN grade I: mild dysplasia limited to the basal one third of the thickness of the corneal or conjunctival epithelium. < CIN grade II: moderate dysplasia confined to the basal two thirds of the corneal or conjunctival epithelium. < CIN grade III, or SCC in situ: severe dysplasia that may involve the entire thickness of the corneal or conjunctival epithelium but, however, does not invade the basement membrane. < Invasive SCC: severe dysplasia with invasion through the basement membrane.
RESULTS
The study population included 162 individuals; 122 males and 40 females. The mean age was 63.4615.8 (range: 27e90). From 162 specimens, there were 163 distinct histopathological diagnoses: in a single case, a patient had both CIN grade II and an amelanotic malignant melanoma. Sixty-nine specimens were from the left eye, and 93 were from the right eye.
The distribution of diagnoses is detailed in table 1. The histopathological features of each benign lesion are detailed in table 2. The clinical appearances of selected limbal lesions from this study are illustrated in figure 1 . Histomorphological images of selected cases are illustrated in figure 2. There were no significant surgical complications noted.
DISCUSSION
In our experience, the differential diagnosis of localised amelanotic limbal tumours includes CIN, invasive SCC, malignant melanoma and a variety of benign entities, which include squamous papilloma, solar elastosis and epithelial hyperplasia, keratosis or reactive atypia. It is notable that, of the 16 benign limbal lesions, 11 (69%) had evidence of solar elastosis. Solar elastosis is a pathognomonic sign in the pathological diagnosis of degenerative diseases of the conjunctiva such as pingueculae and pterygia. It has also been identified as a risk factor for OSSN. In a case control trial, solar elastosis was found in 53.3% of OSSN cases compared to 3.3% of matched controls. 6 The clinical diagnosis of OSSN was accurate in 89.5% of cases. On this basis, we contend that clinical diagnosis alone cannot distinguish benign limbal tumours from OSSN or reliably exclude, albeit an uncommon diagnosis, amelanotic malignant melanoma. In this case series, 1.2% of lesions (two cases) were malignant melanoma. In the first case, it was excised with an associated grade II CIN lesion; surgical margins were free of dysplastic or neoplastic cells. Adjuvant cryotherapy was applied at the time of excision, and postoperatively, the patient was treated with topical 5-fluorouracil 1% (QID, for 2 weeks, continuously). In our practice, the use of topical 5-fluorouracil following excision and cryotherapy is a standard treatment of CIN-type lesions; this is administered irrespective of the involvement of tumour at the margins of the excised specimen. In the second case (previously reported), invasive malignant melanoma was present at the margins of the initial excision and the patient subsequently underwent lamellar corneo-scleral dissection. 7 No histological evidence of residual tumour was found on the second specimen. Clinical recurrence of melanoma was observed 32 months post-excision. The area was ablated with heavy cryotherapy and treated with topical mitomycin-C (0.04%). In both cases, no further recurrence was observed at 6 years follow-up.
Our paper is consistent with the conclusions of other ocular oncologists that OSSN may be clinically misdiagnosed, most commonly as pterygium, pinguecula, dyskeratosis and squamous papilloma. 2 4 In particular, the difficulty in distinguishing clinically between pterygia and OSSN was illustrated in a histopathological review of 533 cases of pterygia, in which 9.8% were shown to have evidence of dysplasia. 8 While certainly less common, the ability of sebaceous cell carcinoma and amelanotic malignant melanoma to simulate OSSN is also recognised. 9 10 The capacity of a clinician to distinguish between grades of CIN, or between CIN and invasive SCC, is also limited. 2 In our study, 4.3% of the total cases (or 5.1% of OSSN) showed signs of squamous malignancy. An Australian review of 288 lesions with OSSN found invasive SCC in 22%. 11 An Indian review of 144 OSSN lesions found a rate of SCC of 44%. 12 However, in both these studies, non-localised and non-limbal lesions were also included in the analyses.
Clinical diagnosis of OSSN may be augmented by the use of exfoliation or impression cytology, both of which are shown to have some predictive diagnostic value. 13 14 The disadvantage is that the superficial nature of the sample, which sometimes only contains keratinised cells, may be falsely negative. Cytological assessment does not provide sufficient information regarding the deeper structure of the lesion, in particular, evidence of invasion. Although not common practice, high-frequency ultrasonography has been used to characterise limbal lesions, particularly tumour thickness and tumour extension. 15 16 Histopathology of the excised tumour, however, is the only reliable method of diagnosis and is generally accepted to be the most appropriate approach to localised lesions presumed to be OSSN. 2 3 The main hazard of clinical misdiagnosis of an excised benign limbal lesion is exposing the patient to unnecessary surgery. In our population, this occurred in close to one in 10 patients. However, in our study, there were no significant surgical complications noted, and the authors contend that the surgery is necessary for an accurate diagnosis to be made and, in particular, to exclude malignant disease.
Although the principal treatment of localised OSSN is excision, the frequency of local recurrence has prompted many surgeons to complement surgery with cryotherapy and/or topical chemotherapeutic agents. Interferon alpha-2b, mitomycin-C (MMC) and 5-fluorouracil (5FU) have all been used as adjuvant therapy for OSSN. Although there is a paucity of clinical trial data, these agents appear to reduce the rates of recurrence.
17e34 Primary treatment with topical chemotherapeutic agents of lesions presumed to be OSSN, but not proven on biopsy, has been described using interferon a 2b, MMC and 5FU. 24e30 In each of these small case series, the results have been favourable. For example, in a trial of MMC, Rozenman and Frucht-Pery described eradication of seven of eight lesions without the need for surgery, a result that appears to be as effective as surgical excision. 28 The authors concluded that, in the hands of an experienced ocular oncologist, primary treatment of localised OSSN with MMC could be considered as long as there was close long-term patient follow-up. In practice, the use of topical chemotherapy as primary treatment is not uncommon. A survey of American ophthalmologists in 2005 reported that, of those who use topical chemotherapy for the treatment of OSSN, only 51% would always biopsy the lesion first, and that 11% never biopsied prior to treatment. 31 Topical chemotherapy has a number of advantages over a surgical approach. It is able to treat the entire ocular surface and is not dependent upon surgical margins. Primary treatment with a chemotherapeutic agent is able to avoid potential complications of surgery, which can include scarring of the conjunctiva and cornea, limbal stem cell failure and incomplete excision of the lesion. Topical chemotherapeutics may be preferred over surgery by some patients, and in the context of patient refusal of surgery, topical chemotherapeutics have been used successfully as primary treatment. 19 Nevertheless, there are serious hazards associated with the use of topical chemotherapy as the primary treatment of lesions presumed to be OSSN based on clinical features alone. Misdiagnosis of a benign lesion as OSSN will unnecessarily expose the patient to a topical chemotherapeutic agent, albeit while avoiding the risks of surgery. Side effects related to topical 5FU and MMC, although typically mild and transient, are common. 28e30 In the authors' experience, of those patients treated with MMC, 34% had an allergic lid reaction and 14% had epiphora related to punctal or nasolacrimal system obstruction. 32 In the authors' experience of 5FU with 62 cases (unpublished), short-term complications include lid toxicity in 52% of patients, keratopathy in 11% and epiphora in 5%. One also needs to be mindful of the potential serious side effects of MMC or 5FU that can include limbal stem cell failure and corneal or stromal melt. 23 33 The most serious danger of primary topical chemotherapy, however, is the risk of misdiagnosing a malignant lesion as CIN. Invasive SCC, although part of the spectrum of disease encompassed by the term OSSN, is associated with significantly greater mortality and morbidity than CIN. 35 Once invasion of the iris or trabecular meshwork occurs, the malignancy has a route for systematic metastatic spread. Orbital exenteration may be required for the control of localised disease, and death from metastatic disease is described in a small percentage of patients. 1 2 35 36 There is no evidence to support the use of topical chemotherapeutics as primary treatment of SCC, and doing so risks under-treating the patient. Similarly, although undiagnosed malignant melanoma may show partial response to topical chemotherapy, this may inadvertently delay diagnosis and expose the patient to the risk of recurrent disease and metastatic spread. Even with adequate surgical treatment of ocular surface malignant melanoma, the risk of recurrence, metastasis and mortality is considerable; Shields et al have documented metastasis in 26% of patients and death in 13% of patients at 10 years. 37 The technique of initial surgery was shown to be an important factor in preventing eventual tumour recurrence, metastasis and death.
On the basis of this study, the authors contend that the use of primary topical chemotherapy exposes a proportion of patients (in this study, approximately, one in 10) unnecessarily to a chemotherapeutic agent. Furthermore, primary chemotherapy would risk under-treating a malignant lesion (in this study, more than one in 20 patients). Under-treatment can be fatal, and the risks of primary chemotherapy for these lesions far outweigh the risks of minor surgery used to obtain an appropriate diagnosis.
CONCLUSION
This study demonstrates that, in our population, 5.5% of localised amelanotic limbal lesions are malignant and that, for an experienced ocular oncologist, the misdiagnosis of localised limbal OSSN occurs in 10.5% of cases. This study also highlights the importance of acquiring a clinical diagnosis before administering a topical chemotherapeutic agent to treat an amelanotic limbal lesion. Figure 2 Histomorphological images of selected limbal lesions included in this study: conjunctival intraepithelial neoplasia (CIN) I (A) (H&E3400); CIN II (B) (H&E3400); CIN III (C) (H&E3200); solar elastosis, but no dysplasia (D) (H&E3200); squamous cell carcinoma (E) (H&E3200); conjunctival melanoma (F) (H&E3200).
